|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here, we found that lncRNA chromatin-associated RNA 10 (CAR10) was upregulated in the tumor tissue of patients with LUAD and enhanced tumor metastasis in vitro and in vivo.
|
30617305 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A histochemical score was developed to evaluate tumor staining, the microvessel density (MVD), and stromal expression patterns for both ADAM12 and CDCP1.
|
27685922 |
2017 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ADAM12 is upregulated in human breast cancers and is a predictor of chemoresistance in estrogen receptor-negative tumors.
|
28148288 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ADAM12 is a member of a disintegrin and metalloproteinase family and has been reported to participate in the development of variety of tumors.
|
28395594 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our goal was to identify the mechanisms by which tumor-associated ADAM12 promotes angiogenesis.
|
28765266 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Knockdown of CAR10 inhibited cell growth in vitro and tumor growth in vivo.
|
27322209 |
2016 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor levels of ADAM12 mRNA were also associated with shorter progression-free and overall survival as well as with lymphatic and vascular invasion, and residual tumor volume following cytoreductive surgery.
|
25926422 |
2015 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We identified ADAM12 (A disintegrin and metalloproteinase 12) as an EphA1-binding partner by yeast two-hybrid screening and found that ADAM12 enhanced ephrin-A1 cleavage in response to transforming growth factor-β1 in primary tumors.
|
23686306 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We now report here that overexpression of ADAM-12 in triple-negative MDA-MB-231 breast cancer cells and breast cancer tumors is likely due to a marked loss of this Z-DNA-mediated transcriptional suppression function.
|
23135915 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We also observed that ADAM12 expression was increased in the tumour vasculature of infiltrating ductal carcinoma of the human breast as compared with little to no expression in normal breast tissue vasculature, suggesting a role for ADAM12 in tumour vessels.
|
23458101 |
2013 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The aim of this study was to analyze the splicing variants of ADAM12 (L and S) and ADAM17 gene expression in melanoma at transcriptional and translational level in comparison with control (non-tumor) tissues.
|
23645517 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Surprisingly, the latter parameter (ADAM12 mRNA) showed a significant opposite correlation to the degree of histologic tumour malignancy.
|
23324579 |
2013 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of ADAM8 and ADAM15 correlated significantly with tumour stage (P=0.048 and P=0.044), and ADAM12 expression correlated with tumour grade (P=0.011).
|
22677901 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The increased expression of ADAM12 protein in the tumor cells and stroma of benign breast diseases was immunohistochemically confirmed.
|
21240579 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Taken together, our results suggest that ADAM12 overexpression results in increased tumor take, tumor size, and metastasis in vivo.
|
21493715 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We hypothesized, however, that the tumor-associated stroma may stimulate ADAM12 expression in tumor cells, on the basis of the fact that TGF-β1 stimulates ADAM12 expression and is a well-known growth factor released from tumor-associated stroma.
|
21875931 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
ADAM12-L mRNA expression is an independent prognostic factor in resected p-stage I lung adenocarcinoma, and is significantly correlated with tumor differentiation stage and postoperative cancer recurrence.
|
19544357 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In many studies, ADAM12 overexpression has been correlated with disease, and ADAM12 has been shown to promote tumor growth and progression in cancer.
|
19601832 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In conclusion, in liver cancers ADAM9 and ADAM12 expression is associated with tumor aggressiveness and progression.
|
12717386 |
2003 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of ADAM12 in cells cultured from the tumour was linked to the presence of multinucleated giant cells.
|
12456779 |
2002 |